Additionally, varying sensitivity of ccRCC cells to HIF2A inhibition has been attributed to different levels of HIF2A expression as well as acquired mutations in the HIF2A complex23,25. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.